Therapy News and Research

RSS

Children and teens with moderate to severe OSA have lower academic grades: Research

The average academic grades of children and teens with moderate to severe obstructive sleep apnea are worse than the grades of students who have no sleep-disordered breathing, according to a research abstract that will be presented Tuesday, June 8, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

8 Jun 2010

Genta presents tesetaxel dose-ranging trial results at ASCO 2010

Genta Incorporated announced today the presentation of results from two dose-ranging trials of tesetaxel, the Company's novel oral tubulin inhibitor. Results showed potential activity in patients with taxane-resistant cancers, along with no evidence of hypersensitivity and a low incidence of nerve damage, both of which are common side effects of standard taxanes.

8 Jun 2010

$Progenics presents Phase 1 PSMA ADC therapy study data for taxane-refractory prostate cancer at ASCO 2010$

Progenics presents Phase 1 PSMA ADC therapy study data for taxane-refractory prostate cancer at ASCO 2010

Progenics Pharmaceuticals, Inc. today presented the design and rationale of an ongoing phase 1 trial of its prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) therapy at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). This phase 1 trial is assessing the safety, tolerability and initial clinical activity of progressively increasing doses of PSMA ADC in patients with progressive, metastatic, hormone-refractory prostate cancer following prior taxane chemotherapy.

8 Jun 2010

Hormone involved in iron metabolism can save mice from deadly acute inflammation: Scientists

In a surprising discovery that someday may lead to new treatments for many inflammatory diseases, University of Utah scientists found that a hormone involved in iron metabolism can save mice from deadly acute inflammation.

8 Jun 2010

Quintiles announces comprehensive suite of PI3K biomarker assays

Quintiles today announced a comprehensive suite of biomarker assays to help biopharmaceutical companies investigate the phosphoinositide 3-kinases (PI3K) cancer survival pathway, the focus of numerous anti-cancer therapies under development. Understanding the PI3K pathway is essential in developing new medicines to inhibit or block this pathway, thereby cutting off a metabolic function needed for certain cancers to survive.

8 Jun 2010

Rice University students develop new device to help children with acute respiratory infections

Gently, gently. That's how babies should be handled, and it was the prime consideration when a team of Rice University seniors developed a device that could save babies' lives.

8 Jun 2010

ARIAD presents updated positive data on AP24534 pan-BCR-ABL inhibitor for CML at 46th ASCO

ARIAD Pharmaceuticals, Inc. today announced updated clinical data from an ongoing Phase 1 study of its investigational pan-BCR-ABL inhibitor, AP24534, in patients with resistant and refractory chronic myeloid leukemia (CML). The data confirm strong clinical evidence of hematologic, cytogenetic and molecular anti-leukemia activity of AP24534, a multi-targeted kinase inhibitor, in heavily pretreated patients with CML, including those with the T315I mutation of the target protein, BCR-ABL.

8 Jun 2010

Final results from Phase 1 trial of OGX-427 for treating solid tumors presented at ASCO 2010

OncoGenex Pharmaceuticals, Inc. today announced final results from a Phase 1 trial. The primary purpose of this trial was to evaluate the safety and tolerability of OGX-427 up to doses of 1000 mg for the treatment of various solid tumors. Patients enrolled had a diagnosis of castrate resistant prostate cancer, breast cancer, ovarian cancer or non-small cell lung cancer.

8 Jun 2010

PhotoMedex announces combination study of XTRAC Velocity laser and Clobex spray for generalized psoriasis

PhotoMedex, Inc. announced today that John Koo, MD will be the principal investigator in a clinical study assessing the efficacy of the XTRAC Velocity® excimer laser in the treatment of generalized psoriasis when used in combination with Clobex® spray. Dr. Koo is Professor and Vice Chairman in the Department of Dermatology at the University of California San Francisco Medical Center. Spearheading the study will be Dr. Koo's colleague, Tina Bhutani, MD.

8 Jun 2010

Medtronic launches iPro2 Professional CGM system to help improve diabetes management

Medtronic, Inc. announced today the launch of iPro2 Professional CGM, a continuous glucose monitoring system used by physicians to help improve diabetes management, in 49 countries around the world. This simplified, yet more advanced fourth-generation CGM system is valuable for detecting high and low glucose fluctuations that can lead to dangerous health complications, which often go undetected with traditional A1C tests (a measurement of glucose control over a two-to-three-month period) and glucose meter measurements.

7 Jun 2010

EKOS receives $2.7M grant to develop product for treatment of ICH

EKOS Corporation announced today that they received a $2.7 million grant from the National Institutes of Health for the development of a product to provide therapy for intracerebral hemorrhagic stroke.

7 Jun 2010

Targeted therapy that benefits patients with metastatic colon cancer fails to help patients with stage III cancer

To the surprise of researchers at Mayo Clinic who led a national clinical trial, a targeted therapy that provides benefit to patients with metastatic colon cancer has failed to help patients with less advanced, stage III cancer. In fact, patients who used the agent, cetuximab, with chemotherapy had outcomes slightly inferior to patients treated with chemotherapy alone.

7 Jun 2010

NPWT clinical hotline for patients

The Advanced Wound Management Division of Smith & Nephew, Inc., a subsidiary of Smith & Nephew plc announced the launch of its Negative Pressure Wound Therapy clinical hotline for patients.

7 Jun 2010

Watermark Medical completes $15M equity investment from CA Technologies

Watermark Medical, Inc., a privately-held medical products and services company currently servicing the sleep-disordered breathing market, today announced the completion of a $15 million equity investment from CA Technologies. This equity investment in Watermark Medical represents CA Technologies' entry into the emerging Software-as-a-Service -based healthcare cloud market.

7 Jun 2010

XCell-Center GmbH announces approval of clinical trial in patients with chronic spinal cord injury

XCell-Center GmbH, Europe's leading provider of adult autologous stem cell therapy, announced approval of the first placebo controlled double blind clinical trial in patients with chronic spinal cord injury.

7 Jun 2010

Preliminary outcomes and trends from Phase III pivotal study of Generex Oral-lyn reported

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today reported preliminary outcomes and trends from the ongoing Phase III pivotal study of Generex Oral-lyn, the Company's proprietary oral insulin spray product.

7 Jun 2010

Phase 1 study data of Keryx' perifosine for recurrent pediatric solid tumors presented at ASCO

Keryx Biopharmaceuticals, Inc. today announced that Phase 1 data of KRX-0401 (perifosine) in recurrent pediatric solid tumors was presented yesterday in the pediatric solid tumor poster discussion session held at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago, IL.

7 Jun 2010

CytRx granted U.S. Patent for bafetinib

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the granting by the U.S. Patent and Trademark Office (USPTO) of U.S. Patent 7,728,131 for oncology drug candidate bafetinib, encompassing claims related to bafetinib's pharmaceutical compound and composition in all indications, as well as for use in methods for treating acute and chronic myelogenous leukemia and acute lymphoblastic leukemia.

7 Jun 2010

Ranibizumab improves vision in patients with visual impairment due to DME: RESTORE study

Results from a new major diabetes eye health study may have the potential to change the way vision loss due to diabetic macular edema, a serious and devastating complication of diabetes, is treated. One year results from the RESTORE study show that 37 per cent of patients treated with ranibizumab only and 43 per cent of those treated with ranibizumab plus laser therapy, had a significant improvement in visual acuity of 10 letters or more on an eye chart, compared to 16 per cent of patients treated with laser alone - the current standard treatment for visual impairment due to DME.

7 Jun 2010

EDEMA4 study results of KALBITOR for treatment of acute attacks of HAE published

Dyax Corp. announced today the publication of results from its second Phase 3, placebo-controlled trial, known as EDEMA4, evaluating KALBITOR (ecallantide) for the treatment of acute attacks of hereditary angioedema. The results, published in the June 2010 issue of the Annals of Allergy, Asthma, and Immunology, indicate that KALBITOR is effective in ameliorating HAE attacks, resolving associated symptoms and preventing attack progression.

7 Jun 2010

Therapy News and Research

Children and teens with moderate to severe OSA have lower academic grades: Research

Genta presents tesetaxel dose-ranging trial results at ASCO 2010

Progenics presents Phase 1 PSMA ADC therapy study data for taxane-refractory prostate cancer at ASCO 2010

Hormone involved in iron metabolism can save mice from deadly acute inflammation: Scientists

Quintiles announces comprehensive suite of PI3K biomarker assays

Rice University students develop new device to help children with acute respiratory infections

ARIAD presents updated positive data on AP24534 pan-BCR-ABL inhibitor for CML at 46th ASCO

Final results from Phase 1 trial of OGX-427 for treating solid tumors presented at ASCO 2010

PhotoMedex announces combination study of XTRAC Velocity laser and Clobex spray for generalized psoriasis

Medtronic launches iPro2 Professional CGM system to help improve diabetes management

EKOS receives $2.7M grant to develop product for treatment of ICH

Targeted therapy that benefits patients with metastatic colon cancer fails to help patients with stage III cancer

NPWT clinical hotline for patients

Watermark Medical completes $15M equity investment from CA Technologies

XCell-Center GmbH announces approval of clinical trial in patients with chronic spinal cord injury

Preliminary outcomes and trends from Phase III pivotal study of Generex Oral-lyn reported

Phase 1 study data of Keryx' perifosine for recurrent pediatric solid tumors presented at ASCO

CytRx granted U.S. Patent for bafetinib

Ranibizumab improves vision in patients with visual impairment due to DME: RESTORE study

EDEMA4 study results of KALBITOR for treatment of acute attacks of HAE published

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News